Christopher W. Ryan, MD, discusses the implications of updated findings from the phase 3 JAVELIN Bladder 100 trial in patients with locally advanced or metastatic urothelial cancer.
Adjuvant everolimus improves recurrence-free survival in patients with fully resected renal cell carcinoma who have a very high risk of disease recurrence.
In a study of patients with high-risk renal cell carcinoma, those who took the drug everolimus daily for up to one year after surgery lived longer without their disease returning (recurrence-free survival, or RFS) than those who did not take everolimus, although the results narrowly missed the clinical trial's prespecified level for statistical significance.
Adjuvant everolimus improves recurrence-free survival in patients with fully resected renal cell carcinoma who have a very high risk of disease recurrence.